Cinemark Holdings, Inc. (NYSE:CNK – Get Free Report) has received an average recommendation of “Moderate Buy” from the eleven analysts that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $26.00.
A number of research analysts recently weighed in on the company. Benchmark reaffirmed a “buy” rating and set a $23.00 price target on shares of Cinemark in a research note on Monday, July 1st. Macquarie increased their target price on Cinemark from $21.00 to $24.00 and gave the stock an “outperform” rating in a report on Tuesday, July 9th. Roth Mkm boosted their price target on shares of Cinemark from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, August 5th. Morgan Stanley raised their price objective on shares of Cinemark from $26.00 to $29.00 and gave the company an “overweight” rating in a research note on Monday, August 5th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Cinemark from $22.00 to $25.00 and gave the stock a “neutral” rating in a research report on Monday, August 5th.
Check Out Our Latest Stock Report on CNK
Insider Activity at Cinemark
Institutional Investors Weigh In On Cinemark
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Point72 DIFC Ltd bought a new stake in shares of Cinemark in the second quarter valued at approximately $144,000. Point72 Asia Singapore Pte. Ltd. boosted its holdings in shares of Cinemark by 38.7% in the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,145 shares of the company’s stock worth $68,000 after acquiring an additional 877 shares during the period. Algert Global LLC bought a new position in shares of Cinemark in the second quarter worth $238,000. Susquehanna Fundamental Investments LLC raised its stake in shares of Cinemark by 5.0% during the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 108,988 shares of the company’s stock valued at $2,356,000 after purchasing an additional 5,199 shares during the period. Finally, Luxor Capital Group LP lifted its holdings in Cinemark by 491.0% during the 2nd quarter. Luxor Capital Group LP now owns 99,295 shares of the company’s stock worth $2,147,000 after purchasing an additional 82,493 shares in the last quarter.
Cinemark Stock Performance
NYSE:CNK opened at $27.71 on Friday. The company has a quick ratio of 1.26, a current ratio of 1.29 and a debt-to-equity ratio of 6.23. Cinemark has a twelve month low of $13.19 and a twelve month high of $29.07. The company has a fifty day moving average of $26.15 and a 200-day moving average of $21.25. The firm has a market capitalization of $3.39 billion, a P/E ratio of 19.11, a P/E/G ratio of 2.12 and a beta of 2.36.
Cinemark (NYSE:CNK – Get Free Report) last announced its quarterly earnings data on Friday, August 2nd. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.25. The firm had revenue of $734.20 million for the quarter, compared to analyst estimates of $691.74 million. Cinemark had a net margin of 5.05% and a return on equity of 41.87%. The business’s quarterly revenue was down 22.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.80 earnings per share. As a group, sell-side analysts anticipate that Cinemark will post 1.33 EPS for the current year.
About Cinemark
Cinemark Holdings, Inc, together with its subsidiaries, engages in the motion picture exhibition business. As of February 16, 2024, it operated 501 theatres with 5,719 screens in 42 states and 13 countries in South and Central America. Cinemark Holdings, Inc was founded in 1984 and is headquartered in Plano, Texas.
Read More
- Five stocks we like better than Cinemark
- How to Plot Fibonacci Price Inflection Levels
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Quiet Period Expirations Explained
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- The Role Economic Reports Play in a Successful Investment Strategy
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Cinemark Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cinemark and related companies with MarketBeat.com's FREE daily email newsletter.